CA-GREEN-STREET
30.1.2024 09:08:27 CET | Business Wire | Press release
Green Street, the preeminent provider of actionable commercial real estate intelligence and analytics, has released its 2024 Pan-European Sector Outlooks, a bundle of in-depth research reports covering commercial real estate. The Outlook reports provide a 360-degree view of the four core property sectors and can be utilized in conjunction with our Market Forecasts tool, which provides five-year forecasts for operating fundamentals and valuation metrics across various scenarios for the top 30 Pan-European markets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240130899540/en/
New Insights! Green Street's 2024 Sector Outlooks and Expanded Market Reports Are Here. Explore Sector Dynamics, Market Fundamentals and Valuation Trends. (Graphic: Business Wire)
The 2024 Pan-European Industrial, Office, Residential and Retail Sector Outlooks include supply/demand analysis, growth forecasts, valuation metrics, and NUTS3 and Market Grades representing long-term growth potential.
“Industrial and retail remain Green Street’s preferred sectors from a long-term hold perspective. Strength of the demand has been fueling industrial rental growth, whilst high incoming yield in retail bolster returns,” explains Marie Dormeuil, Head of European Market Analytics. “On the other hand, office remains a laggard for the fourth consecutive year. The observed yield expansion is not enough to offset the drag in fundamentals entailed by the bifurcation in tenants’ demand in favour of prime offices.”
Below are key takeaways from each sector:
- Industrial: Opportunities Plentiful
M-RevPAM growth – a Green Street proprietary metric that combines effective market rent and occupancy – is forecast to exhibit a more level-playing field than history has played out, and whilst there is a wide dispersion between key European cities, growth is positive across the board. There are signals that values have bottomed and yields are showing tentative signs of tightening. Institutional investors who have been hopeful for a lower price point and/or sought greater assurance on the operating backdrop now have their potential opportunity.
- Retail: Firmer Footings
Europe's downbeat consumer has kept spending despite the uncertain outlook. The pressure on consumer discretionary spend which has been well documented in news headlines has not (yet) necessarily translated into weakening tenant sales. Retailer occupational fundamentals are surprisingly sturdy and, moreover, given the value destruction experienced in the pandemic, several green shoots are emerging in terms of rental growth. Combined with the high initial yields on offer, potential unlevered returns are alluring for centres that are dominant in their catchment. According to Green Street’s Multichannel Desirability Index, which ranks markets in order of where a retailer (and landlord) is most likely to flourish, U.K. cities screen amongst the most favourable places for both ecommerce and physical retailers.
- Office: Crystal Ball Gazing
Key risks to the office sector include a softer macro-outlook (redundancies) and improved productivity due to remote working. The bifurcation in favour of 'A' space that began to assert itself post-pandemic accelerated in '23, eroding further fundamentals for 'B'-quality. Flight to quality by tenants should accelerate operational obsolescence of some of Europe’s more secondary office stock, leading to demolition or conversion to other uses. Developers are likely to find better risk-adjusted (i.e., lower environmental impact, lower development risk) returns on offer by pursuing major refurbishment and/or redevelopment works relative to ground-up new construction projects.
- Residential: More Cheery Than Gloomy
The positive long-term structural trends of solid demand (household formation and immigration) and lack of supply outweigh the headwinds facing the European residential sector. Meanwhile, the outlook for new residential construction is muted as the rise in interest rates has derailed development economics. Pan-European residential asset prices are down ~24% from mid-'22 peak and a bottom might be forming; signals from the fixed income and public equity markets are pointing to moderate upside to private market valuations for the first time after 18 months. Governments' appetite for rent controls and stretched affordability are near-term risks to watch out for.
Request a sample report for more information on Green Street’s Sector Outlooks.
Register now to join the upcoming Pan-European Private Markets Webinar.
To learn more about Green Street’s Market Forecasts Tool, click here.
About Green Street
Green Street is the preeminent provider of actionable commercial real estate research, news, data, analytics, and advisory services in the U.S. and Europe. For more than 35 years, Green Street has delivered unparalleled intelligence and trusted data on the public and private real estate markets, helping investors, banks, lenders, and other industry participants optimize investment and strategic decisions. The firm delivers exclusive market information, conclusion-driven insights, and predictive analytics through a SaaS platform.
Green Street's US Research, Data, and Analytics products along with its global news publications are not provided as an investment advisor nor in the capacity of a fiduciary.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240130899540/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
